CG Oncology's Director Just Deployed $24.8 Million Through His Fund
CG Oncology director Brian Liu deployed $24.8M through Seven Fleet Partners under a Rule 10b5-1 plan at $66.87, following positive Phase 2 cretostimogene readouts. Combined indirect position reaches 1.89M shares
π’ Insider Activity Score: 99/100
Brian Guan-Chyun Liu, independent director of CG Oncology and managing member of Seven Fleet Partners, LP's investment manager, filed a Form 4 on June 29, 2026 disclosing the acquisition of 371,085 common shares at a flat $66.87 per share for approximately $24,814,453 through Seven Fleet Partners, LP β governed by an active, pre-arranged Rule 10b5-1 trading plan. The purchase follows positive Phase 2 study readouts for lead asset cretostimogene grenadenorepvec in bladder cancer. Following the acquisition, Liu's consolidated indirect position reaches exactly 1,886,236 common shares. The plan governed the timing. The Phase 2 data validated the thesis. The flat $66.87 print across a 371,085-share block confirms an institutional negotiated execution.
The Plan-Governed Mechanics at Maximum Scale
A $24.8 million plan-governed purchase is among the largest individual plan-executed buy transactions this series has documented β and the plan designation requires the same temporal insulation treatment applied to every comparable filing, with one important distinction: the plan's execution coincided with positive Phase 2 data, creating analytical tension between the plan's pre-arranged timing and the clinical catalyst's apparent proximity.
A Rule 10b5-1 plan adopted before the Phase 2 readout would have designated this purchase window without knowledge of the specific clinical results that subsequently validated the entry. The plan's pre-arranged character means Liu did not see the Phase 2 data and decide to deploy $24.8 million in response β the plan's parameters were fixed before the readout, and the calendar happened to trigger in the immediate post-data window.
The Flat $66.87 Print: Institutional Block Execution
The perfectly flat $66.87 price across the entire 371,085-share block is the specific execution signature of a negotiated institutional block trade rather than an open-market order working against available intraday depth β the same single-price execution architecture this series documented in the WaterBridge Infrastructure Rule 144 block and the Hut 8 director's flat-price compensation events.
A $24.8 million block clearing at a single uniform price confirms that Seven Fleet Partners' execution desk negotiated the full block at one agreed price rather than accepting the price variation that fragmented intraday execution would produce β the institutional scale of the transaction requiring the specific block-trading infrastructure that delivers price certainty across the full size.
Seven Fleet Partners: The Institutional Vehicle
Seven Fleet Partners, LP is the specific fund vehicle through which Liu, as managing member of the investment manager, deploys institutional capital into CG Oncology β a healthcare-focused investment structure whose $24.8 million commitment reflects fund-level conviction rather than a personal brokerage account purchase.
The combined indirect position of 1,886,236 shares β worth approximately $126.1 million at the $66.87 execution price β represents the fund's complete CG Oncology exposure following the June 29 addition. A healthcare specialist fund building toward an $126 million position immediately following Phase 2 validation is the institutional conviction architecture this series has documented across the OrbiMed Q32 Bio and Enliven analyses β specialist capital following clinical data with scale.
The Cretostimogene Phase 2 Context
Cretostimogene grenadenorepvec is CG Oncology's lead oncolytic immunotherapy candidate for non-muscle invasive bladder cancer β a viral therapy designed to selectively replicate in and destroy cancer cells while stimulating an anti-tumor immune response. Positive Phase 2 readouts in this indication represent the specific clinical validation that de-risks the regulatory pathway and commercial potential for a therapeutic category with limited treatment alternatives for patients who have failed standard intravesical therapies.
For a fund deploying $24.8 million immediately following that readout, the Phase 2 data is the specific binary risk reduction that transforms the investment thesis from probability-weighted clinical risk into nearer-term commercial potential assessment β the same thesis confirmation framework this series applied to the OrbiMed Enliven post-FDA-alignment analysis.
About CG Oncology, Inc.
CG Oncology, Inc. is a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for genitourinary cancers, with cretostimogene grenadenorepvec as its lead candidate for non-muscle invasive bladder cancer. Director Brian Guan-Chyun Liu, through Seven Fleet Partners, LP, holds 1,886,236 common shares worth approximately $126.1 million following the June 29 acquisition of 371,085 shares for approximately $24,814,453. CG Oncology trades on the Nasdaq under the ticker CGON.
How to Think About This
Liu's plan-governed fund purchase scores 99/100 β the maximum score reflecting the specific convergence of an $24.8 million institutional block execution, a healthcare specialist fund's plan-governed timing, and positive Phase 2 cretostimogene data that has validated the underlying clinical thesis at the precise window the purchase executed.
The plan's pre-arranged character provides the temporal insulation. The Phase 2 readout provides the clinical validation. The flat $66.87 institutional block confirms the scale required specialized execution infrastructure. The 1,886,236-share combined position is the fund's complete conviction in cretostimogene's bladder cancer thesis.
The plan ran the timing. The data confirmed the bet. $126 million is now riding on the readout.